Agios Pharm (AGIO) - Net Assets
Based on the latest financial reports, Agios Pharm (AGIO) has net assets worth $1.19 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.30 Billion) and total liabilities ($104.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AGIO asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.19 Billion |
| % of Total Assets | 91.97% |
| Annual Growth Rate | 23.36% |
| 5-Year Change | -7.65% |
| 10-Year Change | 232.72% |
| Growth Volatility | 95.04 |
Agios Pharm - Net Assets Trend (2011–2025)
This chart illustrates how Agios Pharm's net assets have evolved over time, based on quarterly financial data. Also explore Agios Pharm total assets for the complete picture of this company's asset base.
Annual Net Assets for Agios Pharm (2011–2025)
The table below shows the annual net assets of Agios Pharm from 2011 to 2025. For live valuation and market cap data, see Agios Pharm (AGIO) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.19 Billion | -22.57% |
| 2024-12-31 | $1.54 Billion | +90.00% |
| 2023-12-31 | $811.02 Million | -26.33% |
| 2022-12-31 | $1.10 Billion | -14.80% |
| 2021-12-31 | $1.29 Billion | +223.40% |
| 2020-12-31 | $399.50 Million | -37.63% |
| 2019-12-31 | $640.53 Million | -6.84% |
| 2018-12-31 | $687.54 Million | +83.10% |
| 2017-12-31 | $375.50 Million | +4.72% |
| 2016-12-31 | $358.59 Million | +3.90% |
| 2015-12-31 | $345.12 Million | -18.67% |
| 2014-12-31 | $424.37 Million | +222.76% |
| 2013-12-31 | $131.48 Million | +199.52% |
| 2012-12-31 | $43.90 Million | -30.48% |
| 2011-12-31 | $63.14 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Agios Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 50777000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $75.00K | 0.01% |
| Other Comprehensive Income | $2.19 Million | 0.18% |
| Other Components | $1.75 Billion | 146.89% |
| Total Equity | $1.19 Billion | 100.00% |
Agios Pharm Competitors by Market Cap
The table below lists competitors of Agios Pharm ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OMH SCIENCE Group Co Ltd
SHE:300486
|
$1.62 Billion |
|
Jiangnan Mould & Plastic Technology Co Ltd
SHE:000700
|
$1.62 Billion |
|
Shenzhen Microgate Technology Co Ltd
SHE:300319
|
$1.62 Billion |
|
Cosmax Inc
KO:192820
|
$1.62 Billion |
|
Jilin OLED Material Tech Co Ltd
SHG:688378
|
$1.62 Billion |
|
Hyundai Mar&Fi
KO:001450
|
$1.62 Billion |
|
Burkhalter Holding AG
SW:BRKN
|
$1.62 Billion |
|
Hefei Urban Construction Development Co Ltd
SHE:002208
|
$1.62 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Agios Pharm's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,540,956,000 to 1,193,114,000, a change of -347,842,000 (-22.6%).
- Net loss of 412,781,000 reduced equity.
- Other comprehensive income increased equity by 3,711,000.
- Other factors increased equity by 61,228,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-412.78 Million | -34.6% |
| Other Comprehensive Income | $3.71 Million | +0.31% |
| Other Changes | $61.23 Million | +5.13% |
| Total Change | $- | -22.57% |
Book Value vs Market Value Analysis
This analysis compares Agios Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.37x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 10.43x to 1.37x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $2.70 | $28.16 | x |
| 2012-12-31 | $1.88 | $28.16 | x |
| 2013-12-31 | $8.53 | $28.16 | x |
| 2014-12-31 | $12.60 | $28.16 | x |
| 2015-12-31 | $9.22 | $28.16 | x |
| 2016-12-31 | $9.16 | $28.16 | x |
| 2017-12-31 | $8.06 | $28.16 | x |
| 2018-12-31 | $11.97 | $28.16 | x |
| 2019-12-31 | $10.68 | $28.16 | x |
| 2020-12-31 | $5.79 | $28.16 | x |
| 2021-12-31 | $21.37 | $28.16 | x |
| 2022-12-31 | $20.09 | $28.16 | x |
| 2023-12-31 | $14.57 | $28.16 | x |
| 2024-12-31 | $26.62 | $28.16 | x |
| 2025-12-31 | $20.58 | $28.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Agios Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -34.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -764.01%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.09x
- Recent ROE (-34.60%) is below the historical average (-28.46%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -37.55% | -108.56% | 0.11x | 3.08x | $-30.02 Million |
| 2012 | -45.79% | -80.07% | 0.18x | 3.12x | $-24.49 Million |
| 2013 | -29.97% | -154.25% | 0.13x | 1.53x | $-52.56 Million |
| 2014 | -12.61% | -81.86% | 0.13x | 1.16x | $-95.94 Million |
| 2015 | -34.11% | -199.14% | 0.14x | 1.22x | $-152.24 Million |
| 2016 | -55.35% | -283.97% | 0.11x | 1.73x | $-234.33 Million |
| 2017 | -83.80% | -731.60% | 0.07x | 1.64x | $-352.22 Million |
| 2018 | -50.33% | -366.61% | 0.11x | 1.25x | $-414.78 Million |
| 2019 | -64.24% | -348.97% | 0.13x | 1.39x | $-475.52 Million |
| 2020 | -81.94% | -161.11% | 0.24x | 2.14x | $-367.32 Million |
| 2021 | 124.21% | 3875280.74% | 0.00x | 1.11x | $1.48 Billion |
| 2022 | -21.06% | -1627.82% | 0.01x | 1.13x | $-341.88 Million |
| 2023 | -43.41% | -1312.63% | 0.03x | 1.16x | $-433.19 Million |
| 2024 | 43.72% | 1845.92% | 0.02x | 1.08x | $519.63 Million |
| 2025 | -34.60% | -764.01% | 0.04x | 1.09x | $-532.09 Million |
Industry Comparison
This section compares Agios Pharm's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Agios Pharm (AGIO) | $1.19 Billion | -37.55% | 0.09x | $1.62 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Agios Pharm
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment… Read more